Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

Plasma biomarkers that reflect specific amyloid beta (Abeta) proteoforms provide an insight in the treatment effects of Alzheimer’s disease (AD) therapies. Our aim was to develop and validate ready-to-use Simoa ‘Amyblood’ assays that measure full length Abeta(1-42) and Abeta(1-40) and compare their...

Descripción completa

Detalles Bibliográficos
Autores principales: Thijssen, Elisabeth H., Verberk, Inge M. W., Vanbrabant, Jeroen, Koelewijn, Anne, Heijst, Hans, Scheltens, Philip, van der Flier, Wiesje, Vanderstichele, Hugo, Stoops, Erik, Teunissen, Charlotte E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102604/
https://www.ncbi.nlm.nih.gov/pubmed/33958661
http://dx.doi.org/10.1038/s41598-021-89004-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102604/
https://www.ncbi.nlm.nih.gov/pubmed/33958661
http://dx.doi.org/10.1038/s41598-021-89004-x

Ejemplares similares